Google+

New Drug for RET-Driven Cancers

A new cancer drug, known as BLU-667, has shown promise in human clinical trials
A new cancer drug, known as BLU-667, has shown promise in human clinical trials(Credit: vitanovski/Depositphotos)

A new cancer drug known as cancer drug has moved through phase I human trials, and the results are promising. Taken orally, the drug targets what are known as RET-driven cancers, including types of thyroid and lung cancers, which are normally hard to treat. read more